Edition:
United States

ACADIA Pharmaceuticals Inc (ACAD.O)

ACAD.O on Nasdaq

27.24USD
8 Dec 2016
Change (% chg)

$0.16 (+0.59%)
Prev Close
$27.08
Open
$26.88
Day's High
$27.47
Day's Low
$26.47
Volume
1,439,531
Avg. Vol
2,337,544
52-wk High
$42.49
52-wk Low
$16.64

ACAD.O

Chart for ACAD.O

About

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system disorders. The Company's lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson's disease psychosis (PDP). NUPLAZID is a... (more)

Overall

Beta: 4.01
Market Cap(Mil.): $3,279.76
Shares Outstanding(Mil.): 121.11
Dividend: --
Yield (%): --

Financials

  ACAD.O Industry Sector
P/E (TTM): -- 41.20 30.65
EPS (TTM): -2.14 -- --
ROI: -59.19 -0.59 15.23
ROE: -59.22 -1.31 16.56

BRIEF-Acadia Pharmaceuticals initiates phase II trial of Pimavanserin

* Acadia Pharmaceuticals initiates phase II trial of Pimavanserin for adjunctive treatment in patients with negative symptoms of schizophrenia Source text for Eikon: Further company coverage:

Nov 15 2016

BRIEF-UK's CMA says accepted proposals in Acadia's Priory Group deal

Nov 10 UK's Competition and Markets Authority (CMA):

Nov 10 2016

BRIEF-Acadia Pharmaceuticals initiates phase III trial of pimavanserin for adjunctive treatment in patients with Schizophrenia

* Acadia Pharmaceuticals initiates phase iii trial of pimavanserin for adjunctive treatment in patients with Schizophrenia Source text for Eikon: Further company coverage:

Nov 03 2016

BRIEF-Acadia Pharmaceuticals initiates phase II study of pimavanserin in Alzheimer's disease agitation

* Acadia Pharmaceuticals initiates phase II study of pimavanserin in Alzheimer's disease agitation Source text for Eikon: Further company coverage:

Oct 31 2016

GM to add 650 jobs at Spring Hill factory to meet SUV demand

General Motors said it would add a third shift and 650 jobs at its factory in Spring Hill, Tennessee to meet higher demand for its recently launched Cadillac XT5 and GMC Acadia crossover SUVs.

Oct 11 2016

REFILE-DEALTALK-Allergan pays top dollar for 'stepping stones' from neurology to dermatology

Sept 20 Allergan Plc CEO Brent Saunders calls them "stepping stones" - small, bolt-on acquisitions, as opposed to the mega-deals common in the drug industry. And they're expected to boost dealmaking in sectors ranging from neurology to skin care.

Sep 20 2016

Allergan pays top dollar for 'stepping stones' from neurology to dermatology

Allergan Plc CEO Brent Saunders calls them "stepping stones" - small, bolt-on acquisitions, as opposed to the mega-deals common in the drug industry. And they're expected to boost dealmaking in sectors ranging from neurology to skin care.

Sep 20 2016

BRIEF-Acadia Pharmaceuticals reports Q2 2016 financial results

* Acadia Pharmaceuticals reports second quarter 2016 financial results

Aug 04 2016

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $30.94 -0.25
Eli Lilly and Co (LLY.N) $67.19 -0.19
Eisai Co., Ltd (4523.T) ¥6,881 +606.00

Earnings vs. Estimates